OS Therapies Incorporated
AMEX:OSTXBiotechnology
Healthcare
$1.15 +5.81%
+$0.10 today
- Market cap
- $53.83M
- Beta
- -0.95
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$0.91
52W Low $1.15High $2.57
Volume 0.50M
Average 0.71M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$28.71M
FY 2025 · Annual
Net Income
-$28.75M
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.16M | 805 | 4.22K | 2.78K | 363.09K |
| Gross Profit | (1.16M) | (805) | (4.22K) | (2.78K) | (363.09K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 2.17M | 3.29M | 3.22M | 2.84M | 16.36B |
| Selling, General & Admin | 1.5M | 1.15M | 1.12M | 3.97M | 12.34B |
| Operating Expenses | 3.68M | 4.45M | 4.34M | 6.81M | 28.34M |
| Depreciation & Amortization | 805 | 805 | 4.22K | 2.78K | 363.09K |
| EBITDA | (4.84M) | (4.45M) | (4.34M) | (6.83M) | (28.39M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (4.84M) | (4.45M) | (4.34M) | (6.81M) | (28.71M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 249 |
| Interest Expense | 2.58M | 1.81M | 3.45M | 2.05M | 0 |
| Other Income / Expenses | (2.58M) | (1.81M) | (3.45M) | (2.07M) | (48.14K) |
| Income Before Tax | (7.42M) | (6.25M) | (7.79M) | (8.88M) | (28.75M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (7.42M) | (6.25M) | (7.79M) | (8.88M) | (28.75M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.33) | (0.28) | (0.39) | (0.52) | (0.98) |
| EPS (Diluted) | (0.33) | (0.28) | (0.39) | (0.52) | (0.98) |
| 23.1M | 23.1M | 20.05M | 20.87M | 29.25M | |
| 23.1M | 23.1M | 20.05M | 20.87M | 29.25M |
OSTX Earnings Waterfall · TTM
AMEX:OSTX · Revenue to Net Income
Key Ratios
EPS$-1.07
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.7
P/S Ratio0.0
Analysis
$0 of revenue converted into -$35.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.07, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 |
How much revenue does OSTX generate?
OS Therapies Incorporated (OSTX) reported $0.00 of revenue in fiscal 2025.
Is OSTX profitable?
OS Therapies Incorporated (OSTX) reported -$28.75M of net income.
Continue the stock analysis
Jump to another research area for this company.